Why the study?
The EU Safe Hearts Plan requires integration of laboratory medicine as a central component to strengthen cardiovascular prevention, detection, treatment, and monitoring across Europe.
Laboratory medicine must be recognized as a central component in implementing the EU Safe Hearts Plan to ensure equitable cardiovascular health gains across Europe.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We also strengthened our engagement with the EU. For the first time, we were able to contribute to an EU Safe Hearts Plan, with 10 major prevention-focused topics, including personalised prevention using AI, unhealthy nutrition and soft drinks, obesity in adults and children, smoking and nicotine vaping, and vaccination as a form of cardiovascular prevention.”
Laboratory integration into EU cardiovascular policy warrants immediate prioritization; extends the Safe Hearts Plan by specifying five structural priorities for equitable outcomes.
The European Union Safe Hearts Plan provides an opportunity to strengthen cardiovascular prevention, early detection, treatment, and monitoring across Europe. This EFLM position paper argues that laboratory medicine must be recognized as a central component of its implementation. Reliable and harmonized laboratory data underpin cardiovascular risk assessment, diagnosis, therapeutic guidance, longitudinal monitoring, and evaluation of population outcomes. Beyond the minimum health-check dataset, tiered and personalized pathways should integrate established biomarkers, specialist testing, and validated emerging technologies. EFLM proposes five priorities: embedding laboratory expertise in governance; translating core testing into personalized pathways; expanding equitable access through quality-assured decentralized models; linking testing to clinical action and value-based financing; and accelerating responsible innovation while strengthening professional capability. By connecting screening with diagnosis, treatment, and measurable outcomes, laboratory medicine can provide the quality, interpretation, and data infrastructure required to transform the Safe Hearts Plan from policy ambition into equitable cardiovascular health gains across Europe.
No takes yet. Share an insight, caveat, or question.
Gruson et al. (2026) studied Cardiovascular disease. Laboratory medicine was evaluated. Integrating laboratory medicine into the EU Safe Hearts Plan through five key priorities is essential to strengthen cardiovascular prevention, diagnosis, and treatment across Europe.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: